Stoke Therapeutics (NASDAQ:STOK) Earns Buy Rating from Analysts at Chardan Capital

Equities research analysts at Chardan Capital initiated coverage on shares of Stoke Therapeutics (NASDAQ:STOK) in a research report issued on Friday, Marketbeat reports. The brokerage set a “buy” rating and a $24.00 price target on the stock. Chardan Capital’s price target points to a potential upside of 112.39% from the stock’s current price.

Several other analysts have also recently commented on STOK. Leerink Partners assumed coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus price target of $21.29.

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $11.30 on Friday. Stoke Therapeutics has a 1 year low of $4.09 and a 1 year high of $17.58. The firm’s 50-day moving average is $12.49 and its 200-day moving average is $13.58. The company has a market cap of $598.53 million, a P/E ratio of -5.38 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, sell-side analysts predict that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Activity

In related news, General Counsel Jonathan Allan sold 9,696 shares of the business’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the transaction, the general counsel now directly owns 35,142 shares of the company’s stock, valued at approximately $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Edward M. Md Kaye sold 6,786 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the sale, the chief executive officer now owns 61,885 shares of the company’s stock, valued at approximately $803,886.15. The trade was a 9.88 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock worth $809,421 over the last quarter. Corporate insiders own 11.30% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. Quest Partners LLC acquired a new position in Stoke Therapeutics in the second quarter worth approximately $29,000. Nisa Investment Advisors LLC lifted its stake in shares of Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Stoke Therapeutics in the second quarter worth $123,000. Intech Investment Management LLC bought a new position in Stoke Therapeutics during the third quarter valued at about $160,000. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.